Abstract
The outcome of patients with sepsis arises from multiple factors affecting both the host and the invading microorganisms. Even within the setting of adequate antimicrobial use, patients still die of sepsis. Thus, strategies focusing on further therapy targets are an important area of interest for basic and clinical research. Although such adjunctive sepsis therapy has failed to achieve consistent better survival rates so far, the progress in understanding of the pathophysiology of sepsis seen in recent years is so profound, that the possibility that a new and effective treatment may arise should be warmly considered. Indeed, it may be considered that efficacious interventions, such as early and vigorous fluid replacement, strict blood glucose control, low-dose corticosteroid reposition, protective mechanical ventilation and activated-protein C are pathogenic-oriented targets of therapy. In this paper we aim to review some aspects of the pathogenesis of sepsis, focusing on possible targets for adjunctive therapy. Published clinical trials and experimental data supporting such trials are commented on.
Keywords: CD14 receptor, intercellular adhesion molecule-1 (ICAM-1), MAP-kinases, interleukin-1 receptor antagonist, TF/FVII complex, sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Pathogenesis-Oriented Targets for Adjunctive Therapy
Volume: 6 Issue: 2
Author(s): Otelo Rigato, Eliezer Silva and Reinaldo Salomao
Affiliation:
Keywords: CD14 receptor, intercellular adhesion molecule-1 (ICAM-1), MAP-kinases, interleukin-1 receptor antagonist, TF/FVII complex, sepsis
Abstract: The outcome of patients with sepsis arises from multiple factors affecting both the host and the invading microorganisms. Even within the setting of adequate antimicrobial use, patients still die of sepsis. Thus, strategies focusing on further therapy targets are an important area of interest for basic and clinical research. Although such adjunctive sepsis therapy has failed to achieve consistent better survival rates so far, the progress in understanding of the pathophysiology of sepsis seen in recent years is so profound, that the possibility that a new and effective treatment may arise should be warmly considered. Indeed, it may be considered that efficacious interventions, such as early and vigorous fluid replacement, strict blood glucose control, low-dose corticosteroid reposition, protective mechanical ventilation and activated-protein C are pathogenic-oriented targets of therapy. In this paper we aim to review some aspects of the pathogenesis of sepsis, focusing on possible targets for adjunctive therapy. Published clinical trials and experimental data supporting such trials are commented on.
Export Options
About this article
Cite this article as:
Rigato Otelo, Silva Eliezer and Salomao Reinaldo, Pathogenesis-Oriented Targets for Adjunctive Therapy, Endocrine, Metabolic & Immune Disorders - Drug Targets 2006; 6 (2) . https://dx.doi.org/10.2174/187153006777442387
DOI https://dx.doi.org/10.2174/187153006777442387 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Minoxidil Use in Dermatology, Side Effects and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Prevention of Atherosclerosis by Interference with the Vascular Nitric Oxide System
Current Pharmaceutical Design Evidence-Based Pharmacological Treatment of Substance Use Disorders and Pathological Gambling
Current Drug Abuse Reviews Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Current Medicinal Chemistry Nitric Oxide and Dietary Factors: Part V Summary/Conclusion and References
Vascular Disease Prevention (Discontinued) Hypersensitivity to Antineoplastic Agents
Current Pharmaceutical Design Novel Drugs for Chronic Lymphoid Leukemias: Mechanism of Action and Therapeutic Activity
Current Medicinal Chemistry Left Ventricular Hypertrophy in Isolated Aortic Stenosis: Primetime for the Ventricle
Current Pharmaceutical Biotechnology Vascular Inflammation During Human Rickettsioses: An Essential Host Response and a Potential Target for Supplemental Therapy
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Potential Therapeutic Targets in Cirrhotic Cardiomyopathy
Cardiovascular & Hematological Disorders-Drug Targets Endocannabinoid System: A Multi-Facet Therapeutic Target
Current Clinical Pharmacology An Update on Peptide Drugs for Voltage-Gated Calcium Channels
Recent Patents on CNS Drug Discovery (Discontinued) Safety Considerations of the Use of Second Generation Antipsychotics in the Treatment of Major Depression: Extrapyramidal and Metabolic Side Effects
Current Drug Safety Older and Newer Strategies for the Pharmacological Management of Agitation in Patients with Bipolar Disorder or Schizophrenia
CNS & Neurological Disorders - Drug Targets Peironimev-Plus® in the Treatment of Chronic Inflammation of Tunica Albuginea (Peyronie’s Disease). Results of a Controlled Study
Inflammation & Allergy - Drug Targets (Discontinued) ATP-Sensitive Potassium Channels
Current Pharmaceutical Design The Janus Face of Adenosine: Antiarrhythmic and Proarrhythmic Actions
Current Pharmaceutical Design Differentiating Walking from other Activities of Daily Living in Older Adults Using Wrist-based Accelerometers
Current Aging Science L-Arginine Transport in Disease
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Approaches to Minimize Infection Risk in Blood Banking and Transfusion Practice
Infectious Disorders - Drug Targets